Physician profile
Mark D Mosson
NPI 1174765549
$15,047.27
in general payments reported to CMS, 2019-2025
81 companies · $2,091 in 2025
The $2,091 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,075 · 2020: $1,978 · 2021: $2,300 · 2022: $2,252 · 2023: $2,280 · 2024: $2,071 · 2025: $2,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,392 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,392.03 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,179.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,108.57 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $909.94 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $866.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Gilead Sciences, INC. | $805.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $790.48 | 2019-2025 | |
| Novo Nordisk INC | $786.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $717.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $690.00 | 2019-2025 | Spravato |
| Pfizer INC. | $676.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.31 | 2019-2024 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $358.90 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $343.11 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.66 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.92 | 2020-2023 | Xifaxan |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mosson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.